Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Management of bleb failure with 5-fluorouracil augmented bleb needling and sub-bleb Healon-5 injection

Search Title by author or title

Session Details

Session Title: Glaucoma I

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 14:42

Venue: Auditorium C6

First Author: : A.Khafagy EGYPT

Co Author(s): :    H. Elmekawey                    

Abstract Details

Purpose:

To evaluate the efficacy and the safety of 5-fluorouracil augmented bleb needling revision with sub-bleb healone-5 injection for patients with failing filtering bleb.

Setting:

Kasr Eleini Hospital

Methods:

This is a prospective study which included 18 eyes of 16 patients, who had 5-fluorouracil augmented bleb needling revision with sub-bleb healone-5 injection for failing filtering bleb (uncontrolled IOP above 21 mmHg) despite the usage of antiglaucoma medications, between August 2010 and May 2011 at the Ophthalmology Department, All patients were followed up for 6 months.

Results:

The mean preoperative intraocular pressure was (28.83+2.53) mmHg and decreased to (17.83+4.27) mmHg at the end of follow-up period. 10 eyes (56%) achieved absolute success, who had intraocular pressure between 10 and 21 mmHg without further needling revision or topical anti-glaucoma medications during the follow-up, 5 eyes (28%) achieved a qualified success, who had intraocular pressure with the same above range but with topical antiglaucoma medications during the follow-up period. Failure occurred in three eyes (5.5%), needing further surgical intervention.

Conclusions:

5-fluorouracil augmented bleb needling revision with sub-bleb healone-5 injection is an effective and simple technique in controlling the intraocular pressure in eyes with failing filtering bleb, also it avoids the need for further surgical intervention in the majority of patients and has a low incidence of complications.

Financial Disclosure:

NONE

Back to previous